NEW YORK, April 12, 2018 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p04604343
The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness, rising incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.The recombinant glycosylated protein segment is anticipated to grow at the fastest growth rate during the forecast period.The biosimilars market by product is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.The recombinant glycosylated proteins segment is expected to register the highest CAGR during the forecast period.The factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins; presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products; numerous biologic drugs underclass monoclonal antibody, follitropin, and erythropoietin going off-patent; and numerous products in the pipeline.The contract manufacturing segment is estimated to grow at a rapid rate during the analysis period.By type of manufacturing, the biosimilars market is segmented into in-house manufacturing and contract manufacturing.The contract manufacturing segment is expected to grow at the highest CAGR during the forecast period.CMOs provide cost-saving benefits to companies in terms of facilities, equipment, and labor costs.Asia is estimated to register the highest CAGR during the study period.On the basis of region, the biosimilars market is segmented into North America, Europe, Asia, and the Rest of the World (RoW).Asia is expected to grow at the highest CAGR during the forecast period.Many Asian countries such as India, China, South Korea, and Japan have emerged as potential markets for biosimilars.Many emerging economies in the region are also establishing biosimilar pathways.Moreover, leading market players are outsourcing manufacturing and R&D activities to countries in the Asia Pacific region due to the availability of highly skilled resources at lower costs. In addition to this, the low per capita consumption, rapid growth in economies, trade links, and the rise in medical tourism are accelerating the growth of the Asian market.The primary interviews conducted for this report can be categorized as follows:• By Company Type - Tier 1 – 70% and Tier 2 – 30%• By Designation – C-level – 62%, Director-level – 21%, Others – 17%• By Region – North America – 50%, Europe – 20%, Asia– 30%The key players in the biosimilars market include Pfizer (US), Sandoz (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy's Laboratories (India), Celltrion (South Korea), and Samsung BiologicsResearch Coverage:The report analyses the biosimilars market by products, type of manufacturing, disease, and region.Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years.In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.Key benefits of buying the Report:This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.The report provides insights on the following pointers:• Market Penetration: Comprehensive information on the product portfolios of the top players in the biosimilars market• Product Development/Innovation: Detailed insights on product approvals, R&D activities, and product launches in the biosimilars market• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biosimilars across geographies• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars marketRead the full report: https://www.reportlinker.com/p04604343
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected]
US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/the-biosimilars-market-is-expected-to-reach-usd-23-63-billion-by-2023-from-usd-5-95-billion-in-2018--at-a-cagr-of-31-7-300629019.html
SOURCE Reportlinker
